|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
A Systematic Review of Economic Evaluations Assessing the Cost-Effectiveness of Licensed Drugs Used for Previously Treated Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Negative Advanced/Metastatic Non-Small Cell Lung Cancer.
|
31583605 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Only for the small proportion of patients with metastatic NSCLC and genomic-driven tumors with EGFR or anaplastic lymphoma kinase (ALK)-sensitizing mutations (5%-15%), and possibly <i>BRAF</i> mutations and <i>ROS</i> rearrangements, have initial treatment recommendations remained unchanged, with specific tyrosine kinase inhibitors as the preferred therapy.
|
30642913 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC.
|
31482479 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up.
|
31346927 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the KEYNOTE-024 trial, pembrolizumab demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) versus Standard-of-Care (SoC) platinum-based doublets for first-line treatment of PD-L1 -positive (≥50%) metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with no EGFR mutations or ALK translocations.
|
30642550 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases.
|
30786826 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
RCTs of second/third line treatments in participants with advanced/metastatic NSCLC and negative/low expression of Anaplastic Lymphoma Kinase (ALK) and of Epidermal Growth Factor Receptor (EGFR) were included.
|
31023244 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Brigatinib, approved in May 2016, is an ALK inhibitor specifically indicated for ALK-positive metastatic NSCLC in patients who have progressed on or resistant to crizotinib therapy.
|
31109722 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with stage IV NSCLC treated with an ALK inhibitor at the University of Colorado Cancer Center from 2009 through November 2017 were identified retrospectively.
|
30599201 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A high pretreatment PLR is independently associated with poor survival in stage IV NSCLC with MPE and in a subgroup of epidermal growth factor receptor and anaplastic lymphoma kinase wild-type NSCLC.
|
30886226 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, lorlatinib 100 mg once daily has a unique safety profile to be considered when prescribed, based on the recent U.S. Food and Drug Administration approval, for the treatment of patients with ALK-positive metastatic non-small cell lung cancer previously treated with a second-generation ALK TKI.
|
30890623 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite their remarkable efficacy in metastatic non-small cell lung cancer (NSCLC), EGFR- and ALK-targeted therapies have not been shown to confer any survival benefit in stage III disease, even in subsets of patients with driver mutations.
|
30711973 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Rapid progression of metastatic non-small cell lung cancer (NSCLC) after discontinuation of tyrosine kinase inhibitors or anaplastic lymphoma kinase (ALK) inhibitors has been described and is associated with a poor prognosis.
|
30476657 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.
|
29458286 |
2018 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the USA, alectinib is indicated for the treatment of adults with ALK-positive metastatic NSCLC.
|
30030733 |
2018 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9.
|
29959809 |
2018 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the role of conventional radiotherapy (RT) and stereotactic body radiotherapy (SBRT) in patients with epidermal growth factor (EGFR)-mutant or anaplastic lymphoma kinase (ALK) rearrangement-positive metastatic non-small cell lung cancer (NSCLC).
|
29275314 |
2018 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The anaplastic lymphoma kinase inhibitor crizotinib has been granted approval for the treatment of patients with ROS1 positive metastatic non-small-cell lung cancer by the Food and Drug Administration on 2016.
|
28893136 |
2018 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Brigatinib is an FDA-approved oral anaplastic lymphoma kinase (ALK) inhibitor for treatment of metastatic non-small cell lung cancer (NSCLC).
|
30253203 |
2018 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study.
|
29844259 |
2018 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified 33 ROS1-positive and 115 ALK-positive patients with stage IV NSCLC.
|
29981925 |
2018 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
This article summarizes the milestones in the development of brigatinib leading to this first global approval for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.
|
28597393 |
2017 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The FDA has approved the ALK inhibitor brigatinib for patients with metastatic non-small cell lung cancer who cannot take crizotinib or whose disease worsened despite its use.
|
28536155 |
2017 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
On the basis of its significant activity results, brigatinib received approval by the FDA for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.
|
29119148 |
2017 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
It was granted accelerated approval in 2014 to treat anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer patients who have progressed on or are intolerant to crizotinib.
|
27738095 |
2017 |